First line of the email MUST contain NCT # and Site #.
CONTACT
Lead
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants must have been treated in the postmarketing setting with at least 1 infusion of lisocabtagene maraleucel (Liso-cel) used for the treatment of Mantle Cell Lymphoma (MCL) according to the FDA-approved indication and dose range (ie, per the US Prescribing Information) and with a product meeting the specifications for commercial release approved in the USA
You may not be if
Participants known to be participating in investigational studies at the time of liso-cel infusion.
Participants treated with non-conforming CAR T-cell product.
Clareo Health | A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
